Standard BioTools to sell mass cytometry business to Element Biosystems for $5.5M after terminating Multiplex Bio deal

STANDARD BIOTOOLS INC.

Standard BioTools terminated its July 28, 2026 agreement to sell the mass cytometry business to Multiplex Bio and paid a $1.5 million termination fee.
On September 30, 2026, the company signed a Share and Asset Purchase Agreement with Element Biosystems, a GMT Venture subsidiary, for $5.5 million cash on a cash-free, debt-free basis.
GMT Venture agreed to pay $1.0 million toward the Multiplex termination fee and provided an equity commitment letter to fund Element's obligations; no financing condition applies.
The Element deal requires Standard BioTools stockholder approval and consummation of its pending merger with Treeline Biosciences; closing is expected by end of 2026.
The company says the Element deal improves net cash for the Treeline exchange ratio by about $15 million versus Multiplex; on specified termination, Standard BioTools owes Element $1.0 million.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.